1887

Abstract

A piperacillin/tazobactam (PT) restriction was initiated at our institution on 15 July 2012 requiring clinical pharmacy or infectious diseases approval for durations exceeding 72 h. A retrospective review was undertaken to determine whether this restriction decreased PT usage and/or rates of acute renal failure (ARF) (defined as a 50 % increase or 0.5 mg dl increase in serum creatinine from baseline). Patients prescribed at least 1 day of PT with a creatinine clearance of ≥ 39 ml min at the time of initiation in the 3 months prior to the restriction were compared with patients in the 5 months after restriction implementation. Overall, 115 unique patients were included in the pre-implementation group and compared with 117 unique patients in the post-implementation group. The pre-implementation group received a mean of 5.22 days of PT, compared with 4.71 days in the post-implementation group (P = 0.224). Ten per cent (12/115) of patients in the pre-implementation group developed ARF compared with 9.17 % (11/120) of patients in the post-implementation group (P = 0.0309). Ninety-five patients in the pre-implementation group and 91 in the post-implementation group received combination therapy with vancomycin. ARF occurred in 11.6 % (11/95) of those in the pre-implementation group and 12.1 % (11/91) in the post-implementation (P>0.05). Overall, 11.8 % (22/186) of patients who received therapy with PT and vancomycin developed ARF, compared with 1.7 % (1/56) who received PT monotherapy (P < 0.0001). This restriction resulted in a numeric reduction in the number of PT days in the post-implementation group and a significant reduction in the rate of ARF.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000211
2016-02-01
2019-09-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/2/195.html?itemId=/content/journal/jmm/10.1099/jmm.0.000211&mimeType=html&fmt=ahah

References

  1. Burgess L. D., Drew R. H.. ( 2014;). Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34: 670–676 [CrossRef] [PubMed].
    [Google Scholar]
  2. Davies S. W., Efird J. T., Guidry C. A., Dietch Z. C., Willis R. N., Shah P. M., Sawyer R. G.. ( 2015;). Top guns: the “maverick” and “goose” of empiric therapy. Surg Infect (Larchmt) 16: 1–10 [PubMed].[CrossRef]
    [Google Scholar]
  3. Dellit T. H., Owens R. C., McGowan J.E., Jr., Gerding D. N., Weinstein R. A., Burke J. P., Huskins W. C., Paterson D. L., Fishman N. O., other authors. ( 2007;). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44: 159–177 [CrossRef] [PubMed].
    [Google Scholar]
  4. Dunn K., O'Reilly A., Silke B., Rogers T., Bergin C.. ( 2011;). Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. Int J Clin Pharm 33: 208–214 [CrossRef] [PubMed].
    [Google Scholar]
  5. Gomes D. M., Smotherman C., Birch A., Dupree L., Della Vecchia B. J., Kraemer D. F., Jankowski C. A.. ( 2014;). Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 34: 662–669 [CrossRef] [PubMed].
    [Google Scholar]
  6. Moenster R. P., Linneman T. W., Finnegan P. M., Hand S., Thomas Z., McDonald J. R.. ( 2014;). Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect 20: O384–O389 [CrossRef] [PubMed].
    [Google Scholar]
  7. Yam P., Fales D., Jemison J., Gillum M., Bernstein M.. ( 2012;). Implementation of an antimicrobial stewardship program in a rural hospital. Am J Health Syst Pharm 69: 1142–1148 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000211
Loading
/content/journal/jmm/10.1099/jmm.0.000211
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error